To evaluate temporal trends in the prescription of commonly used drugs before and after different types of metabolic and bariatric surgery interventions in a large and unselected population, highlighting the significance of these trends in the context of rising obesity rates.
Key Findings:
Significant reductions in the use of antihypertensives, glucose-lowering agents, and lipid-lowering drugs were observed post-surgery, with specific percentages indicating the extent of reduction.
Higher rates of drug discontinuation were noted, particularly with malabsorptive procedures compared to restrictive ones, suggesting a need for tailored post-operative care.
Improvements in comorbidities were associated with the type of bariatric surgery performed, indicating the importance of procedure selection.
Interpretation:
The study indicates that bariatric surgery not only aids in weight loss but also significantly reduces the need for medications related to obesity-associated comorbidities, with variations based on the type of surgical procedure, which has important implications for clinical practice.
Limitations:
The study was limited to a single region in Italy, which may affect generalizability and introduce regional biases.
Data on drug use was based on dispensing records, which may not reflect actual adherence, potentially skewing the results.
Conclusion:
Bariatric surgery leads to significant reductions in medication use for obesity-related comorbidities, highlighting its effectiveness as a treatment option and suggesting avenues for future research.
